Dec 08, 2020
PDL Announces Timeline for Voluntarily Delisting from Nasdaq
Nov 11, 2020
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
Oct 29, 2020
PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020
Oct 02, 2020
PDL BioPharma Completes Spin-Off of LENSAR
Aug 31, 2020
PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
Aug 28, 2020
PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024
Aug 12, 2020
PDL BioPharma Enters Into Settlement Agreement with Wellstat
Aug 06, 2020
PDL BioPharma Reports 2020 Second Quarter Financial Results
Jul 30, 2020
PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital
Jul 30, 2020
PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020
May 21, 2020
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
May 18, 2020
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
May 07, 2020
PDL BioPharma Reports 2020 First Quarter Financial Results
May 05, 2020
PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders
Apr 30, 2020
PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020
Mar 11, 2020
PDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020
Mar 04, 2020
PDL BioPharma to Announce 2019 Fourth Quarter and Full Year Financial Results on March 11, 2020
Feb 28, 2020
PDL BioPharma Enters into Cooperation Agreement with Engine Capital
Feb 25, 2020
PDL BioPharma to Participate in the Cowen and Company 40th Annual Health Care Conference
Dec 19, 2019
PDL BioPharma Announces Upcoming Changes to its Board of Directors